EP3897179A1 - Composition pulvérulente pour la production d'un produit buvable - Google Patents

Composition pulvérulente pour la production d'un produit buvable

Info

Publication number
EP3897179A1
EP3897179A1 EP21701686.4A EP21701686A EP3897179A1 EP 3897179 A1 EP3897179 A1 EP 3897179A1 EP 21701686 A EP21701686 A EP 21701686A EP 3897179 A1 EP3897179 A1 EP 3897179A1
Authority
EP
European Patent Office
Prior art keywords
composition
extract
concentrate
per
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21701686.4A
Other languages
German (de)
English (en)
Inventor
Rolf Sorg
Tobias KÜHNE
Wilhelm Messer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PM International AG
Original Assignee
PM International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PM International AG filed Critical PM International AG
Publication of EP3897179A1 publication Critical patent/EP3897179A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
    • A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A23L2/395—Dry compositions in a particular shape or form
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/40—Tea flavour; Tea oil; Flavouring of tea or tea extract
    • A23F3/405—Flavouring with flavours other than natural tea flavour or tea oil
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Definitions

  • the invention relates to food supplements, in particular a powdery composition for producing a solution for oral administration and the use of the inventive composition for producing a solution for oral administration.
  • Food supplements are usually administered orally. To improve the absorption of valuable ingredients in the gastrointestinal space, to simplify the intake of the dietary supplement and to avoid complications when taking, these dietary supplements are often taken as an aqueous solution. In order to reduce microbial infestation and increase chemical stability, effervescent tablets or powders are usually offered for this purpose, which are then dispersed in water by the user in order to produce a drinkable solution.
  • Dietary supplements are also used to improve the supply of muscle and nerve cells.
  • a good supply of oxygen is seen as essential, especially for muscle and nerve cells.
  • attempts are made to improve the oxygen supply in the human body through exercise, good nutrition or medicine.
  • the oxygen supply of each individual can still be improved, if necessary with the help of food supplements.
  • Oxidative stress ie the formation of reactive oxygen species in the body, is considered to be potentially disease-causing and it is worth striving to reduce oxidative stress.
  • Nitric oxide (NO) acts as a radical scavenger, which can scavenge reactive oxygen species, and as a signal transmitter. A slightly increased concentration of endogenous nitric oxide is considered positive.
  • the present invention is directed to these goals and achieves at least some of the objects by a powdery composition for the preparation of a solution (as a dietary supplement) for oral administration, the composition per 100 g, 1 g to 85 g of at least one monosaccharide, 0.18 Contains g to 0.70 g of at least one steviol glycoside, 1.5 g to 10 g citric acid, 0.3 g to 3 g vitamin C, at least two other vitamins and an extract from green tea (Camellia sinensis).
  • a solution can be prepared at room temperature (approx. 20 ° C).
  • a suspension is considered to be a solution and is included in the invention as long as the suspended parts are essentially also drunk and do not remain at the bottom of the drinking vessel.
  • Compositions in which essential constituents sediment on the bottom of the drinking vessel are not considered a solution for the purposes of the invention.
  • the at least one monosaccharide leads to the rapid dissolution of the powder in water and to a good taste. That carries at least one steviol glycoside also contributes to the good taste.
  • a particularly healthy product is obtained through the combination of at least one monosaccharide and at least one steviol glycoside, since the proportion of monosaccharides can be reduced and the solution still contains at least one monosaccharide as an energy source.
  • the citric acid also contributes to the special taste experience. Artificial sweeteners are not required and preferably the composition does not contain any artificial sweeteners.
  • composition is surprisingly microbially stable. Artificial preservatives are not required and preferably the composition does not contain artificial preservatives.
  • Vitamin C and at least two other vitamins are vitamins that are not part of the green tea extract. Vitamin C and the at least two other vitamins are preferably added as pure substances.
  • the composition contains 5 g to 80 g of the at least one monosaccharide, 0.19 g to 0.60 g of the at least one steviol glycoside, 2.5 g to 7.0 g citric acid and 0.4 g to 2 g per 100 g , 5 g vitamin C.
  • the composition preferably contains 4.14 mg to 3000 mg of the extract from green tea (Camellia sinensis), preferably from green tea leaves, per 100 g.
  • the extract contains valuable polyphenols and catechins and contributes to the special taste of the solution.
  • the composition contains a concentrate from broccoli (Brassica oleracea italica), in particular from seeds, sprouts and / or sprouts of broccoli, and / or a concentrate from broccoli (Brassica oleracea italica), in particular from florets and / or stems of broccoli, and / or an extract from the onion (Allium cepa, in particular Allium cepa alliaceae), in particular from the onion of the onion, and / or an extract from the apple (Malus domestica), in particular from the apple fruit, in particular from the peel of the apple fruit, and / or a Extract from the acerola (Malpighia glabra, in particular Malpighia glabra linne), in particular from the fruit of the acerola, and / or a concentrate from the tomato (Lycopersicon esculentum), in particular from the fruit of the tomato, and / or a concentrate from the turmeric ( Curcuma longa), especially from the root of turmeric ( Cur
  • the composition preferably contains a total of 0.10 g to 0.75 g per 100 g of the composition of these extracts and / or concentrates.
  • the composition preferably contains a concentrate from broccoli (Brassica oleracea italica), in particular from seeds, sprouts and / or sprouts of broccoli, and a concentrate from broccoli (Brassica oleracea italica), in particular from florets and / or stems of broccoli, and an extract from the onion (Allium cepa, in particular Allium cepa alliaceae), in particular from the onion of the onion, and an extract from the apple (Malus domestica), in particular from the apple fruit, in particular from the peel of the apple fruit, and an extract from the acerola (Malpighia glabra, in particular Malpighia glabra linne), in particular from the fruit of the acerola, and a concentrate from the tomato (Lycopersicon esculentum), in particular from the fruit of the tomato, and a concentrate from the turmeric (Curcuma longa), in particular from the root the turmeric, and a concentrate from the garlic (Allium sativum), especially
  • the composition contains a total of 0.10 g to 0.75 g per 100 g of the composition of these extracts and concentrates.
  • extract denotes a dried extract from corresponding plant parts, the extract preferably being obtained with the help of an organic solvent and / or water and with a drug-extract ratio between 120: 1 and 10: 1.
  • a "concentrate” denotes a dehydrated product made from corresponding parts of the plant. Extracts and concentrates from fruits, leaves, onions, bark (without cork), roots, rhizomes, tubers, seeds, germs, sprouts, florets and stems offer a high content of valuable, vegetable secondary metabolites such as polyphenols, depending on the type of plant. Polyphenols are aromatic compounds that contain two or more hydroxyl groups directly bound to an aromatic ring and are classified as secondary plant metabolites.
  • Polyphenols have various health-promoting effects, in particular some polyphenols have an antioxidant effect.
  • the concentrates and extracts of various plants provide a variety of health-promoting secondary plant metabolites, vitamins and polyphenols. Such a composition can increase the bioavailability of the compounds contained in the composition. This results in a composition that has a particularly health-promoting effect and supports a balanced diet particularly well.
  • the inventors have discovered that the addition of the extracts and / or concentrates mentioned in the patent application has a positive effect on the dissolving behavior of the powder in water and the taste of the solution.
  • the composition preferably contains 4 mg to 200 mg, preferably 5 mg to 50 mg, one or more ingredients per 100 g, selected from an extract from pepper (Piper nigrum) and an extract from ginger (Zingiber officinale).
  • the composition preferably contains 4 mg to 200 mg, preferably 5 mg to 50 mg, of an extract from pepper (Piper nigrum), 0.25 mg to 2 g, preferably 0.45 mg to 1.5 g, per 100 g Curcumin compound and 4 mg to 200 mg, preferably 5 mg to 50 mg, of an extract from ginger (Zingiber officinale).
  • the curcumin compound can be a curcumin-cyclodextrin complex, in particular a curcumin-gamma-cyclodextrin complex.
  • the extract from the ginger is preferably an extract from the rhizome of the ginger (Zingiber officinale).
  • the composition preferably contains 2.3 mg to 5 g, more preferably 4.14 mg to 3 g, of extract from coffee (Coffea arabica), preferably from the coffee bean, per 100 g.
  • the composition preferably contains 0.025 mg to 2 g, more preferably 0.045 mg to 1.5 g, extract from the sour cherry (Prunus cerasus), preferably from the cherry of the sour cherry, per 100 g.
  • the composition preferably contains 0.025 mg to 2 g, more preferably 0.045 mg to 1.5 g, of extract from cabbage (Brassica oleracea acephala), preferably from leaves of cabbage, per 100 g.
  • the composition preferably contains 0.25 mg to 2 g, more preferably 0.45 mg to 1.5 g, of extract from turmeric (Curcuma longa), preferably from the root of turmeric, per 100 g.
  • the composition preferably contains 0.025 mg to 2 g, more preferably 0.045 mg to 1.5 g of extract from broccoli (Brassica oleracea italica), preferably from broccoli florets, per 100.
  • the composition preferably contains 0.025 mg to 2 g, more preferably 0.045 mg to 1.5 g, extract from the blueberry (Vaccinium corymbosum), preferably from the fruit of the blueberry, per 100 g.
  • extract from the blueberry Vaccinium corymbosum
  • the composition preferably contains an extract from the coffee (Coffea arabica), preferably from the coffee bean, an extract from the
  • Sour cherry (Prunus cerasus), preferably from the cherry of the sour cherry, an extract from the cabbage (Brassica oleracea acephala), preferably from leaves of the cabbage, an extract from the turmeric (Curcuma longa), preferably from the root of the turmeric the broccoli (Brassica oleracea italica), preferably from the broccoli florets, an extract from the blueberry (Vaccinium corymbosum), preferably from the fruit of the blueberry, and the extract from green tea (Camellia sinensis), preferably from leaves of green tea, whereby the composition of these extracts contains a total of 0.01 g to 5 g per 100 g.
  • These extracts, especially in combination, can increase the concentration of endogenous nitric oxide.
  • the composition preferably contains 100 mg to 1000 mg of caffeine per 100 g of the composition.
  • the caffeine can come from a guarana extract.
  • the at least two further vitamins are selected from B vitamins (B vitamin embodiment).
  • the composition preferably contains 1 g to 85 g, more preferably 5 to 80 g, of the at least one monosaccharide per 100 g of the composition.
  • the composition preferably contains 0.19 g to 0.60 g of the at least one steviol glycoside per 100 g of the composition.
  • the composition preferably contains 2.5 g to 7.0 g citric acid per 100 g of the composition.
  • the composition preferably also contains 50 mg to 200 mg of algae powder and optionally 3 g to 12 g, more preferably 4 g to 10 g, of guarana extract per 100 g of the composition.
  • the guarana extract can contribute caffeine, among other things.
  • the algae powder is preferably a powder made from brown algae.
  • the composition preferably contains dextrose as the at least one monosaccharide.
  • the composition preferably contains 100 mg to 1500 mg niacin, 20 mg to 270 mg pantothenic acid, 5 mg to 100 mg pyridoxine, 4 mg to 72 mg riboflavin, 5 mg to 70 mg thiamine per 100 g of the composition as B vitamins , 10 pg to 10 mg cyanocobolamine, 0.5 mg to 7 mg biotin and 0.5 mg to 12 mg folic acid.
  • Dextrose dissolves very quickly in water and, in combination with the other ingredients, gives the solution its special taste. Dextrose also improves the absorption of certain ingredients. This embodiment helps in particular to improve the oxygen supply to the tissues.
  • the at least two further vitamins are selected from vitamins A and E (vitamins A and E embodiment).
  • the composition preferably contains 1500 pg to 4000 pg retinol equivalents and 60 mg to 120 mg ⁇ -tocopherol equivalents per 100 g of the composition.
  • the composition preferably contains 5 g to 80 g, more preferably 5 g to 70 g, particularly preferably 5 g to 42 g, of the at least one monosaccharide per 100 g of the composition.
  • the composition preferably contains 0.19 g to 0.60 g of the at least one steviol glycoside per 100 g of the composition.
  • the composition contains in in this embodiment, 2.0 g to 7.0 g citric acid per 100 g of the composition.
  • the composition preferably contains fructose as the at least one monosaccharide.
  • the composition preferably contains 200 pg to 350 pg selenium per 100 g of the composition.
  • the composition preferably contains 35 g to 85 g dietary fiber per 100 g of the composition.
  • the dietary fibers are preferably vegetable fibers from flafer, peas, rice and / or apples. Fructose dissolves very quickly in water and, in combination with the other ingredients, gives the solution its pleasant taste. It is astonishing that a solution can be produced with this special composition despite the high fiber content.
  • composition contains digestive enzymes (amylase, protease, lactase, cellulase and lipase) and a curcumin-gamma-cyclodextrin complex.
  • digestive enzymes as mylase, protease, lactase, cellulase and lipase
  • curcumin-gamma-cyclodextrin complex it is also preferred that the composition contains gram-positive non-sporulating bacteria, such as, for example (Lactobacillus acidophilus, Lactobacillus reuteri) and / or gram-positive sporulating bacteria, such as, for example, Bacillus species.
  • composition can also contain adjuvants such as beetroot powder (concentrate of beetroot juice, maltodextrin), gum arabic, pectin and / or guar gum.
  • adjuvants such as beetroot powder (concentrate of beetroot juice, maltodextrin), gum arabic, pectin and / or guar gum.
  • the invention also relates to the use of a composition according to the invention for producing a solution for oral administration - or in other words - a method for producing a solution for oral administration.
  • the powdery composition is dissolved in water to produce the solution.
  • 8 g to 16 g of the composition are added to about 180 mL of water at about room temperature and mixed so that a solution is obtained.
  • the product is preferably consumed once a day.
  • 100 g of the powdery composition of this example contain:
  • 100 g of the powdery composition of this example contain:
  • the powdered compositions quickly dissolve in water to form healthy, drinkable solutions with no artificial preservatives or sweeteners.
  • the solutions have an attractive appearance and a good taste, offer a high bioavailability of the ingredients and improve the supply of oxygen, important vitamins, polyphenols and other substances to the human body.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pulvérulente pour la production d'une solution à usage oral, la composition contenant, pour 100 g, 1 g à 85 g d'au moins un monosaccharide, 0,18 g à 0,70 g d'au moins un glycoside de stéviol, 1,5 à 10 g d'acide citrique, 0,3 g à 3 g de vitamine C, au moins deux autres vitamines et un extrait de thé vert (Camellia sinensis).
EP21701686.4A 2020-03-11 2021-01-14 Composition pulvérulente pour la production d'un produit buvable Pending EP3897179A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102020106691.0A DE102020106691A1 (de) 2020-03-11 2020-03-11 Pulverförmige Zusammensetzung zur Herstellung eines trinkfähigen Produktes
PCT/EP2021/050683 WO2021180381A1 (fr) 2020-03-11 2021-01-14 Composition pulvérulente pour la production d'un produit buvable

Publications (1)

Publication Number Publication Date
EP3897179A1 true EP3897179A1 (fr) 2021-10-27

Family

ID=71899793

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21701686.4A Pending EP3897179A1 (fr) 2020-03-11 2021-01-14 Composition pulvérulente pour la production d'un produit buvable

Country Status (6)

Country Link
US (1) US20230117459A1 (fr)
EP (1) EP3897179A1 (fr)
CN (1) CN115243553A (fr)
DE (1) DE102020106691A1 (fr)
LU (1) LU101682B1 (fr)
WO (1) WO2021180381A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413558B1 (en) * 1999-07-19 2002-07-02 The Proctor & Gamble Co. Compositions, kits, and methods for providing and maintaining energy and metal alertness
EP2098121B1 (fr) * 2006-12-22 2013-09-18 Kao Corporation Boisson a base de the vert conditionnee dans un contenant
EP2186418A4 (fr) * 2007-08-30 2011-11-16 Kao Corp Boisson en poudre instantanée
AT506014A1 (de) * 2007-10-24 2009-05-15 Karl Mag Dr Zehethofer Functional drink
DE202016103333U1 (de) * 2016-06-23 2017-06-19 Frank Holtey Nahrungsergänzungsmittel

Also Published As

Publication number Publication date
LU101682B1 (de) 2021-09-13
WO2021180381A1 (fr) 2021-09-16
US20230117459A1 (en) 2023-04-20
CN115243553A (zh) 2022-10-25
DE102020106691A1 (de) 2021-09-16

Similar Documents

Publication Publication Date Title
Almeida et al. Properties and applications of Morinda citrifolia (noni): A review
Chandrika et al. Gotu Kola (Centella asiatica): nutritional properties and plausible health benefits
Achi et al. Phytochemical, proximate analysis, vitamin and mineral composition of aqueous extract of Ficus capensis leaves in South Eastern Nigeria
US7919114B2 (en) Compositions and methods using Morinda citrifolia
US20090252758A1 (en) Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
US20040146592A1 (en) Nutraceutical mangosteen composition
DE10150824B4 (de) Konzentrat, seine Herstellung und Verwendung
EP2207435B1 (fr) Boisson fonctionnelle
Parra et al. An overview on various aspects of plant Berberis Lycium Royale
D’Angelo et al. The impact of supplementation with Pomegranate fruit (Punica Granatum L.) on sport performance
LU101682B1 (de) Pulverförmige Zusammensetzung zur Herstellung eines trinkfähigen Produktes
DE202009002126U1 (de) Spurenelement enthaltende Zusammensetzung
EP3941220B1 (fr) Complément alimentaire et aliment
EP3849343B1 (fr) Composition, complément alimentaire, composition en tant que complément alimentaire pour enfants et procédé de fabrication
LU101728B1 (de) Zusammensetzung, Nahrungsergänzungsmittel, Zusammensetzung als Nahrungsergänzungsmittel für Kinder und Verfahren zur Herstellung
DE202007007745U1 (de) Bier enthaltendes Mischgetränk
DE202020107209U1 (de) Zusammensetzung enthaltend eine Kombination von Amla-Extrakt, Holunderextrakt und nukleotidhaltigem Hefeextrakt
Ranjah et al. International Journal of Food and Allied Sciences
Dula et al. Antioxidant and other health promoting properties of herbs
DE102020215803A1 (de) Zusammensetzung enthaltend eine Kombination von Amla-Extrakt, Holunderextrakt und nukleotidhaltigem Hefeextrakt
Khan NUTRITIONAL COMPOSITION, PHYTOCHEMICAL AND ANTIOXIDANT ACTIVITY OF STEM OF (Nymphaea nouchali) AND (Nymphaea rubra
Rao Trigonella foenum-graecum: A common indian spice with medicinal properties
EP4154898A1 (fr) Compositions de complément à base de plantes
Dohre et al. In Support of human health by Capsicum frutescens, Daucus carota, and Pisum sativum
Joginpally B Nandhini Reddy, Lakshmi Naganathan, ANV Sunitha, R Bhagya Jyothi, B Chaitanya and JVC Sharma

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240410